Milken Institute56 min
Superbugs: Avoiding an Existential Threat to Humanity
Esther Krofah, Valeria Bortolaia, Ron Daniels, Peter Jackson, Peter Piot, Lance Price, Sneha Kemka
Conference Presentation, Panel
The Scale and Severity of Antimicrobial Resistance (AMR)
- Current annual death tolls from drug resistance are approximately 700,000 globally, with 50,000 in Europe and North America alone.
- Projections without intervention estimate 10 million annual deaths by 2050, a figure exceeding current cancer mortality rates.
- Economic impacts are estimated to reach $100 trillion in global GDP losses by 2050.
- Routine medical procedures, including cancer therapies, surgeries, and chronic disease management, face increased risk due to the inability to treat infections effectively.
- The UK's global leadership, driven by figures like Sally Davis and Jim O'Neill, successfully elevated AMR to a priority on the UN General Assembly, G7, G20, and World Economic Forum agendas.
- Sepsis is identified as a primary driver of AMR mortality, with global estimates of 20–30 million annual cases, potentially leading to 20–30 million deaths by 2050 if untreated.
Pharmaceutical Innovation and Market Failures
- Major pharmaceutical companies have largely withdrawn from antibiotic R&D, creating a void in the development pipeline for new therapeutics.
- Innovation is now concentrated in Small and Medium-sized Enterprises (SMEs); a UK survey identified 23 SMEs managing 47 projects, yet they hold only £47 million in total capital.
- The global pool of experts actively developing new AMR therapeutics is estimated at fewer than 150, compared to over 4,000 funded by Cancer Research UK.
- A significant market failure exists where new, precise antibiotics must be preserved as a last resort, preventing the high-volume sales required to recoup R&D investments.
- Solutions proposed include "pull mechanisms" to reward developers financially regardless of volume, with the UK preparing to pilot such an incentive model in the first half of 2019.
- Current R&D efforts rely heavily on government initiatives like CARB-X and BARDA to bridge the gap between pre-clinical research and early clinical trials.
Sepsis, Diagnostics, and Precision Medicine
- Sepsis mortality rates are three times higher when the underlying cause is a resistant pathogen compared to a sensitive one.
- Current diagnostic approaches for sepsis rely on generic, physiology-based criteria that fail to account for individual patient variations (e.g., age, chronic conditions).
- The panel advocates for "precision medicine" utilizing interoperable data systems, machine learning, and patient registries to identify which patients require antimicrobials.
- A major barrier to adoption is the "translational gap" where pathogen identification results do not influence clinical prescribing behavior due to lack of reimbursement or clinician pressure.
- The UK has launched a "Longitude Prize" initiative to develop point-of-care diagnostics capable of distinguishing bacterial from viral infections within 24 hours.
One Health: Agriculture, Environment, and Global Disparities
- The "One Health" framework asserts that human, animal, and environmental health are interconnected; resistant bacteria can transfer from farm animals to humans via meat, vegetables (via manure fertilizer), and environmental contamination.
- In industrialized nations, antibiotic use in animals often exceeds human use, with significant portions used as growth promoters rather than for treating sick animals.
- The discovery of the MCR1 gene, which confers resistance to colistin (a last-resort antibiotic), was linked to the use of colistin as a growth promoter in the Indian poultry industry.
- In low- and middle-income countries (LMICs), challenges include over-the-counter antibiotic availability, counterfeit drugs, and sub-optimal dosing, leading to widespread misuse.
- Multi-drug resistant tuberculosis (MDR-TB) remains a critical threat in Eastern Europe, China, India, and sub-Saharan Africa, killing over 1 million people annually.
- Denmark serves as a success model: a 1996 ban on antibiotic growth promoters reduced vancomycin-resistant enterococci (VRE) in chicken products from 80% to undetectable levels within 15 years.
Strategic Recommendations and Next Steps
- Immediate Priorities: Focus on infection control (sanitation, hygiene, vaccination), antimicrobial stewardship, and appropriate antibiotic use, as these yield faster results than drug development.
- Agricultural Reform: Implement bans on growth promoters and non-therapeutic antibiotic use, supported by measurable monitoring systems to track resistance levels in animal populations.
- Retailer Leverage: Utilize consumer purchasing power and retailer policies (e.g., refusing products with antibiotic residues) to drive changes in farming practices.
- Reimbursement Reform: Shift healthcare payment models to reward value-based outcomes, such as reduced resistance rates and effective stewardship, rather than volume of drugs prescribed.
- Data and Awareness: Launch global awareness campaigns to empower patients and change clinician behavior, ensuring data on antibiotic resistance is standardized and actionable.
- Supply Chain Stability: Address shortages of existing generic antibiotics caused by manufacturer plant closures due to reduced prescribing volumes.
- Global Equity: Ensure LMICs have access to essential antibiotics while simultaneously implementing regulations to prevent misuse, avoiding a scenario where "saving the baby" (access to drugs) loses the "bathwater" (resistance control).